159 related articles for article (PubMed ID: 25040327)
1. Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Jalalat SZ; Cohen PR
Int J Dermatol; 2015 Jun; 54(6):e213-6. PubMed ID: 25040327
[No Abstract] [Full Text] [Related]
2. Vandetanib (Caprelsa) for medullary thyroid cancer.
Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
[No Abstract] [Full Text] [Related]
3. The safety of vandetanib for the treatment of thyroid cancer.
Tsang VH; Robinson BG; Learoyd DL
Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
[No Abstract] [Full Text] [Related]
5. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
8. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
9. Kinase inhibitors for advanced medullary thyroid carcinoma.
Schlumberger M; Massicotte MH; Nascimento CL; Chougnet C; Baudin E; Leboulleux S
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):125-9. PubMed ID: 22584717
[TBL] [Abstract][Full Text] [Related]
10. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
Duplomb S; Benoit A; Mechtouff-Cimarelli L; Cho TH; Derbel O; Peix JL; de la Fouchardière C
J Clin Oncol; 2012 Jan; 30(2):e21-3. PubMed ID: 22162581
[No Abstract] [Full Text] [Related]
11. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
13. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
14. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
15. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Valerio L; Bottici V; Matrone A; Piaggi P; Viola D; Cappagli V; Agate L; Molinaro E; Ciampi R; Tacito A; Ramone T; Romei C; Elisei R
Endocr Relat Cancer; 2020 Jan; 27(2):97-110. PubMed ID: 31804969
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
Maciel LMZ; Magalhães PKR
Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
20. Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma.
Kothari R; Kreimer S; Nadel H; Seeley H; Hartman G; Meister KD
JCO Precis Oncol; 2024 Jan; 8():e2300257. PubMed ID: 38207224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]